Nasdaq suspends Windtree (WINT): -80% in 24 hours, moving to OTC and BNB strategy in jeopardy

Related

How to Buy Spot Bitcoin ETFs

In January of last year, spot Bitcoin ETFs were...

The Trends That Dominated the Bitcoin Market in 2025

In this 2025, the Bitcoin market has been dominated...

Tether Juventus bid targets full Exor exit and 1 billion euro investment plan

Today, on 12 December 2025, Tether submitted a binding...

Share

The suspension from Nasdaq for Windtree Therapeutics (ticker WINT), due to non-compliance with listing requirements and accompanied by an intraday collapse of –80%, has sparked strong fears among investors and raised questions about the recent initiative of treasury in BNB (initial commitment of $60 million with potential up to $200 million), indicating an already fragile financial balance.

According to the collected data, the stock went from about $0.48 before the notice to $0.11 at the close on August 21, 2025, confirming the very substantial intraday loss. Industry analysts monitoring small-cap biotech companies note that similar situations typically lead to a compression of capitalization and a significant reduction in liquidity in the first weeks following the delisting.